44 results about "MRSA infection" patented technology

Disclosed herein are hydroxylthienoquinolones and related compounds and their pharmaceutically acceptable salts useful as antiviral agents and having the general formulain which the variables R2, R6, and R7 are defined herein. Certain compounds provided herein possess potent antibacterial, antiprotozoal, or antifungal activity and are particularly efficacious for the treatment of MRSA infections. The invention also provides pharmaceutical compositions, pharmaceutical compositions containing a hydroxylthienoquinolone in combination with one or more other active agent, and methods of treating microbial infections in animals by administering an effective amount of a hydroxylthienoquinolone or related compound to an animal suffering from a microbial infection.

The invention relates to synthesis and application of an antibacterial medicine ASC for targeted treatment of MRSA (methicillin-resistant staphylococcus aureus) and SAU (staphylococcus aureus) infection and for treatment of super bacterium infection by being cooperated with antibiotics. The effective concentration of the ASC for treating the MRSA infection is 2 mug / mL; the efficacy is 4 times higher than the efficacy of standard medicine oxacillin; the dosage of 35 mg / kg can realize the specific effect treatment on mouse heart and lung MRSA infection, and the MRSA colonization quantity in liver, spleen and kidney tissues of the mouse can be obviously reduced. The ASC is also a broad spectrum inhibitor of antibiotic drug resistant target protein metal beta-lactamase, and can be cooperated with beta-lactamase, aminoglycoside and tetracycline type medicine to realize the targeted treatment of SAU infection; through the dose of 1 mug / mL, the curative effects of antibiotics can be improvedto 4 to 128 times; through the dose of 64 or 8 mug / mL, the curative effect of Xianfeng V on NDM-1 or CcrA producing medicine-resistance bacteria E.coli is improved by 32 times.

The present invention includes compositions and methods for diagnosing and treating CA-MRSA infections in patients. The methods are based on the finding that combining cefoxitin and a synthetic penicillin in a treatment regimen results in a synergistic effect of the two drugs, an effect that is related to PBP4 activity in CA-MRSA isolates. Also provided is a CA-MRSA-specific biomarker which can be used to detect the presence of a CA-MRSA infection in a patient.

The invention discloses a de-malonate monoacyl azalomycin F, a preparation method thereof and the application thereof to preparation of an MRSA (Methicillin-resistant Staphylococcus aureus) infection therapeutic drug. Azalomycin F reacts in an alkaline methanol solution to produce de-malonate azalomycin F, the de-malonate azalomycin F is separated to obtain the de-malonate monoacyl azalomycin F. The MRSA activity test shows that the MIC (Minimal Inhibitory Concentration) of the obtained de-malonate monoacyl azalomycin F to MRSA tester strain is 0.25-0.50 Mug / mL, which is 8-16 times of that of azalomycin F, and the de-malonate monoacyl azalomycin F has enhanced stability and water solubility. The de-malonate monoacyl azalomycin F has remarkable MRSA activity and a favorable development prospect and can be used for preparing an MRSA infection therapeutic drug.

The invention relates to the synthesis and application of a class of antibacterial drugs ASC for targeted therapy of methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SAU) infections and synergistic antibiotic therapy for superbug infections. The effective concentration of ASC in the treatment of MRSA infection is 2 μg / mL, which is 4 times stronger than that of the standard drug oxacillin; the dose of 35 mg / kg specifically treats MRSA infection in the heart and lung of mice, and makes the liver, spleen, The colonization of MRSA in kidney tissue was significantly reduced. ASC is also a broad-spectrum inhibitor of metallo-β-lactamase, a class of antibiotic-resistant target proteins, and can synergize with β-lactam, aminoglycoside and tetracycline drugs to target the treatment of SAU infection: the dose of 1 μg / mL makes these antibiotics effective A 4-128-fold increase, the dose of 64 or 8 μg / mL makes Pioneer V resistant to NDM-1 or CcrA-producing bacteria E.coli The curative effect is increased by 32 times.

The present invention specifically relates to the application of clemastine fumarate in anti-MRSA preparations. MRSA has high toxicity and is resistant to most common clinical antibiotics, and the strain is widely distributed in the daily environment, so it is a difficult pathogenic strain. In order to develop an active substance that has an inhibitory effect on the above-mentioned drug-resistant bacteria, the present invention screened and verified that clemastine fumarate has a good inhibitory effect on MRSA from clinical drugs, and is expected to be applied to the development of drugs related to anti-MRSA infection.